<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Substance use during pregnancy: Overview of selected drugs</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Substance use during pregnancy: Overview of selected drugs</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Substance use during pregnancy: Overview of selected drugs</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Grace Chang, MD, MPH</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles J Lockwood, MD, MHCM</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew J Saxon, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen Eckler, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 10, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H837816035"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Use and misuse of substances by pregnant individuals occurs globally. Identification of substance use allows for interventions aimed at reducing maternal and fetal risk by reducing or stopping substance use or initiation of medications. Challenges to care of people who use substances during pregnancy include a lack of screening tools that function across cultures and languages, barriers to patient disclosure of substance use, and limited treatment and risk reduction resources.</p><p>This topic will explore the impact of selected substances on pregnancy. Screening for substance use and laboratory testing are discussed separately. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4799.html" rel="external">"Substance use during pregnancy: Screening and prenatal care"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/13846.html" rel="external">"Testing for drugs of abuse (DOAs)"</a>.)</p><p></p><p>Related content specific to alcohol and opioid use in pregnancy are presented elsewhere.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4798.html" rel="external">"Alcohol intake and pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14381.html" rel="external">"Fetal alcohol spectrum disorder: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4790.html" rel="external">"Opioid use disorder: Overview of treatment during pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5016.html" rel="external">"Prenatal substance exposure and neonatal abstinence syndrome (NAS): Management and outcomes"</a>.)</p><p></p><p>In this topic, when discussing study results, we will use the terms "woman/en" or "patient(s)" as they are used in the studies presented. We encourage the reader to consider the specific counseling and treatment needs of transmasculine and gender-expansive individuals.</p><p class="headingAnchor" id="H846605835"><span class="h1">CHALLENGES IN ASSESSING DRUG IMPACT</span><span class="headingEndMark"> — </span>The effect of any illicit or misused substance on pregnancy outcome is difficult to ascertain because data are scarce and confounded by the influence of other factors, including polysubstance use, poor nutrition, poverty and related adverse stressors, comorbidities, inadequate prenatal care, and environmental factors, such as the COVID-19 pandemic, which saw an increase in overdose deaths in pregnant persons [<a href="#rid1">1</a>]. In addition, reliable ascertainment of the extent of drug use during pregnancy and drug dose/purity are very difficult.</p><p>The clinical manifestations of substance use disorders are diverse and differ by drug and setting (eg, usual dose, overdose, withdrawal). Combined with the physiologic changes of pregnancy and the clinical manifestations of coexisting pregnancy-related disease, diagnosis of patients presenting with serious clinical abnormalities can be challenging. For example, cocaine and amphetamine overdose can cause hypertension and seizures, similar to preeclampsia/eclampsia.</p><p class="headingAnchor" id="H4255449384"><span class="h1">OPIOIDS</span><span class="headingEndMark"> — </span>An online patient-oriented infographic is available to help with screening and counseling for <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.acog.org%2Fwomens-health%2Finfographics%2Fopioid-use-disorder-and-pregnancy%3Futm_source%3Dhigher-logic%26utm_medium%3Demail%26utm_content%3Dmar-08%26utm_campaign%3Dacog2023-digest&amp;token=zNfqmduxR%2BfAkerMiR252AGB%2FofyZuHcOHEiyns6gwEiwm6OKSEXqSGcnnrpPuuylyaQxMGWFh2ocxjywOI9cFBh7B7EwqGR0CX4vugtNd4L7Sq6aoSzO5Ez%2F%2Bk3GY6cvzGmCdWFsdAejfwUyCkB0d852bPtkWRGpOCq8M2IwwTikg1r3B9r1epuaHKDmz13&amp;TOPIC_ID=128152" target="_blank">opioid use disorder in pregnancy</a>.</p><p class="headingAnchor" id="H3135355032"><span class="h2">Prevalence</span><span class="headingEndMark"> — </span>While opioid use is a global problem, opioid use by pregnant individuals living in the United States has increased to the level of a public health crisis.</p><p class="bulletIndent1"><span class="glyph">●</span>A US cohort study of nearly 22,000 pregnancies occurring between 1990 and 2021 reported an overall opioid exposure rate of 2.8 percent [<a href="#rid2">2</a>]. Between 1999 and 2014, US maternal opioid use quadrupled from 1.5 to 6.5 per 1000 delivery hospitalizations based on data from 28 states [<a href="#rid3">3,4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In 2007, nearly 23 percent of pregnant patients who were enrolled in the Medicaid program (data from 46 states) filled an opioid prescription during pregnancy [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>By 2017, the estimated rate of maternal opioid-related diagnoses (MOD) had increased by nearly 5 per 1000 delivery hospitalizations compared with 2010, from 3.5 (95% CI 3.0-4.1) to 8.2 (95% CI 7.7-8.7) [<a href="#rid6">6</a>]. Analysis of discharge records from 47 states and the District of Columbia found MOD rates ranged from 1.7 (Nebraska) to 47.3 (Vermont) per 1000 delivery hospitalizations.</p><p></p><p>While some countries reported decreasing prevalence of opioid use during similar time periods, prevalence rates varied by income groups and did not drop for individuals in the lowest quintile of area-level income [<a href="#rid7">7</a>]. At least one study has reported higher opioid prescriptions for individuals also prescribed psychotropic medications compared with those who were not (26.5 versus 10.7 percent) [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/d/html/7804.html" rel="external">"Opioid use disorder: Epidemiology, clinical features, health consequences, screening, and assessment"</a>.)</p><p class="headingAnchor" id="H36166246"><span class="h2">Complications from use</span><span class="headingEndMark"> — </span>Opioid use disorders are associated with a number of risks, including financial, social, and psychological issues, that cause psychosocial stress, exposure to violence [<a href="#rid9">9</a>], and limit treatment and other life options [<a href="#rid10">10</a>].</p><p>Multiple obstetric complications have been associated with opioid use disorder in pregnancy [<a href="#rid11">11-13</a>]. However, it is difficult to establish the extent to which these problems are due to opioids, opioid withdrawal, or other drugs used versus coexistent maternal medical, nutritional, psychological, and socioeconomic issues. Complications include:</p><p class="bulletIndent1"><span class="glyph">●</span>Abruptio placentae </p><p class="bulletIndent1"><span class="glyph">●</span>Fetal death</p><p class="bulletIndent1"><span class="glyph">●</span>Intraamniotic infection</p><p class="bulletIndent1"><span class="glyph">●</span>Fetal growth restriction</p><p class="bulletIndent1"><span class="glyph">●</span>Fetal passage of meconium</p><p class="bulletIndent1"><span class="glyph">●</span>Preeclampsia</p><p class="bulletIndent1"><span class="glyph">●</span>Premature labor and delivery</p><p class="bulletIndent1"><span class="glyph">●</span>Premature rupture of membranes</p><p class="bulletIndent1"><span class="glyph">●</span>Placental insufficiency </p><p class="bulletIndent1"><span class="glyph">●</span>Miscarriage</p><p class="bulletIndent1"><span class="glyph">●</span>Postpartum hemorrhage</p><p class="bulletIndent1"><span class="glyph">●</span>Septic thrombophlebitis</p><p></p><p>In addition to the above list, one study reported the increase in maternal cardiac events from 2002 to 2014 paralleled the rise in opioid use among pregnant persons in the United States and raised questions about possible causality [<a href="#rid14">14</a>]. Nonpregnant chronic opioid users have been reported to have an increased dose-dependent risk of myocardial infarction [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H2532915542"><span class="h2">Medication for opioid use disorder</span><span class="headingEndMark"> — </span>The American College of Obstetricians and Gynecologists and the American Society of Addiction Medicine recommend treatment of opioid use disorder in pregnancy with medications rather than medically supervised detoxification [<a href="#rid16">16</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medication preferred to ongoing substance use</strong> – For pregnant patients with opioid use disorder, medication treatment with <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> or <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> offers overwhelming advantages (eg, oral administration, known dose and purity, safe and steady availability, improved maternal/fetal/neonatal outcomes) compared with continued use of heroin or other illicit opioids. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Options of </strong><a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a><strong> or </strong><a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> – Both buprenorphine and methadone have proven efficacy in treating pregnant patients with opioid use disorder; neither is clearly superior as each has benefits and drawbacks  (<a class="graphic graphic_table graphicRef87713" href="/d/graphic/87713.html" rel="external">table 1</a>). One advantage of buprenorphine is that neonatal opioid withdrawal syndrome is typically less severe in neonates born to individuals treated with buprenorphine compared with methadone [<a href="#rid17">17</a>]. There has been longer experience with methadone.</p><p></p><p>Regardless of which medication is chosen to treat opioid use disorder, treatment with medical therapy presents a unique opportunity to bring women into medical and obstetric care systems. Clinical use of <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> and <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> in pregnant patients, as well as fetal/neonatal effects, are discussed in detail separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4790.html" rel="external">"Opioid use disorder: Overview of treatment during pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/87238.html" rel="external">"Opioid use disorder: Pharmacotherapy with methadone and buprenorphine during pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5010.html" rel="external">"Prenatal substance exposure and neonatal abstinence syndrome (NAS): Clinical features and diagnosis", section on 'Opioids'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5016.html" rel="external">"Prenatal substance exposure and neonatal abstinence syndrome (NAS): Management and outcomes"</a>.)</p><p></p><p class="headingAnchor" id="H1933929889"><span class="h1">CANNABIS (MARIJUANA)</span><span class="headingEndMark"> — </span>An online patient-oriented infographic is available to help with screening and counseling for <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.acog.org%2Fwomens-health%2Finfographics%2Fmarijuana-and-pregnancy%3Futm_source%3Dhigher-logic%26utm_medium%3Demail%26utm_content%3Dmar-08%26utm_campaign%3Dacog2023-digest&amp;token=OwPZhWzvbrGAVeV%2BkILoCdN7WYUuyvUpAwNWZFrH2lh2iccEe%2FVg4PJ2mQXyw5a7I%2BV9cThhRvEzSGgEv%2FBzvaQ6vyaK%2F4J5k3eJwEH4cRoAS7HBFpcoAuSnqaNMm72q5JmxUoMheuVf%2BWVplhZPus7K%2BDbmARVTxa26Cz5JvL5xooD6jWYORzGE5PEPVIHH&amp;TOPIC_ID=128152" target="_blank">cannabis use in pregnancy</a>. </p><p class="headingAnchor" id="H678007571"><span class="h2">Advisory during pregnancy</span><span class="headingEndMark"> — </span>While there are conflicting data regarding the risk of preterm delivery and low birth weight in women who smoke cannabis during pregnancy, the American College of Obstetricians and Gynecologists (ACOG), the American Academy of Pediatrics (AAP), and the Academy of Breastfeeding Medicine (ABM) advise avoiding cannabis use during pregnancy and lactation because of concerns for the neurodevelopmental impact on the developing fetus and child [<a href="#rid18">18-20</a>]. Potential risks are of particular concern for pregnant individuals as there are data supporting increasing potency of cannabis products [<a href="#rid21">21,22</a>]. </p><p class="headingAnchor" id="H2861458500"><span class="h2">Epidemiology</span><span class="headingEndMark"> — </span>Cannabis (marijuana) is one of the most commonly used substances during pregnancy [<a href="#rid19">19</a>]. </p><p class="headingAnchor" id="H1249386974"><span class="h3">Prevalence of use</span><span class="headingEndMark"> — </span>Prevalence of pregnancy-specific use varies according to maternal age, racial or ethnic background, and socioeconomic status. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Any use</strong> – Self-reported rates of use vary from 2 to 7 percent in many studies to approximately 30 percent among young, urban, and socioeconomically disadvantaged individuals [<a href="#rid23">23-33</a>]. In a US national survey from 2013 to 2019, the percent of pregnant persons reporting cannabis use ranged from 4.9 percent (in the past month) to 15.2 percent (in the past year) [<a href="#rid34">34</a>]. By comparison, among nonpregnant women, 11.8 percent reported marijuana use in the past month, and 19.5 percent in the past year. After adjusting for sociodemographic characteristics, past-year marijuana use was 2.3 to 5.1 times more likely among pregnant persons, and 2.1 to 4.6 times more likely among nonpregnant women reporting past-year tobacco smoking, alcohol use, or other illicit substance use compared with those without other substance use. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dependence</strong> – One United States study of self-reported survey data noted that, among individuals who reported cannabis use in the past year, 18 percent of pregnant women met criteria for Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV) cannabis abuse and/or dependence [<a href="#rid28">28</a>]. Depression and anxiety have been associated with cannabis use in pregnancy [<a href="#rid35">35-37</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nausea as a risk factor</strong> – At least one study has reported that nausea and vomiting in pregnancy may be a risk factor for prenatal cannabis use [<a href="#rid38">38</a>]. Paradoxically, chronic cannabis use can also cause a hyperemesis syndrome, of which patients and clinicians may be unaware [<a href="#rid39">39</a>]. (See  <a class="medical medical_review" href="/d/html/141176.html" rel="external">"Cannabinoid hyperemesis syndrome"</a>.)</p><p></p><p class="headingAnchor" id="H3642983437"><span class="h3">Evidence of increasing use</span><span class="headingEndMark"> — </span>In the United States, cannabis use by pregnant women appears to be increasing, possibly related to perceived lack of risk, legalization, and changing social attitudes [<a href="#rid31">31,40</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increasing use</strong> – Three reviews of United States survey data, including two from a California data set, reported that rates of cannabis use among pregnant individuals increased from nearly 3 to approximately 7 percent during 2001 to 2017 while rates of alcohol and cigarette use dropped during the same time period [<a href="#rid30">30,41,42</a>]. The 2017 and 2019 iterations of the United States National Survey on Drug Use and Health (NSDUH) reported increasing rates of cannabis use across all age groups in the study cohort (ages 12 to 44 years) and during the first trimester [<a href="#rid30">30,43</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical importance</strong> – Any increase in use is important because approximately 50 percent of females who use cannabis will continue to do so while pregnant and there is evidence of increasing potency of cannabis [<a href="#rid21">21,22,44</a>]. In a 2017 review of the United States Pregnancy Risk Assessment Monitoring System (PRAMS), 9.8 percent of women reported cannabis use prior to pregnancy, 4.2 percent during pregnancy, and 5.5 percent after pregnancy [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/d/html/7797.html" rel="external">"Cannabis use and disorder: Epidemiology, pharmacology, comorbidities, and adverse effects"</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Impact of COVID-19 pandemic</strong> – A northern California health care system that performs universal toxicology testing in early pregnancy reported increased maternal cannabis use during the first eight months of the pandemic compared with the 15 months prior (6.75 percent pre-pandemic to 8.14 percent during the pandemic for a 25 percent increase, 95% CI 12-40 percent) [<a href="#rid45">45</a>]. Potential reasons for increased maternal use included pandemic-specific stressors such as social isolation, financial and psychological distress, increased burden of childcare, changes in healthcare, and concerns for infection. In California, cannabis retailers were considered an essential business and remained open to the public. </p><p></p><p class="headingAnchor" id="H3517253163"><span class="h3">Perceived lack of risk</span><span class="headingEndMark"> — </span>A study from the US NSDUH database reported that the percentage of females who believed that regular cannabis use was of no risk during pregnancy increased from 4.6 percent in 2005 to 19.0 percent in 2015 [<a href="#rid46">46</a>]. In addition, a qualitative study found that patients reported trust in cannabis retailers and perceived them as being "knowledgeable, nonjudgmental, and caring" [<a href="#rid47">47</a>]. A 2022 US population-based survey reported that living in a state requiring point-of-sale warning signs appeared to have opposite effects on the prevalence of beliefs about cannabis impact during pregnancy, with pregnant cannabis users having a greater prevalence of beliefs that cannabis was safe and pregnant nonusers having a greater prevalence of beliefs that use was unsafe [<a href="#rid48">48</a>]. </p><p>The previous studies highlight the importance of obstetric providers offering education about the potential risks of prenatal cannabis use. Obstetric professionals have access to the most recent and accurate findings and can serve as objective experts, particularly since people who use cannabis appear to find warning labels unconvincing and rely instead on cannabis retailers for information. </p><p class="headingAnchor" id="H2568138388"><span class="h2">Pharmacokinetics</span><span class="headingEndMark"> — </span>Chemical products from cannabis use are transferred both across the placenta and into breast milk [<a href="#rid49">49-52</a>]. One study of 54 breast milk samples collected from cannabis users between 2014 and 2017 reported that over 60 percent of milk samples had detectable levels of delta-9-tetrahydrocannabinol (delta-9-THC) up to approximately six days after last reported cannabis use [<a href="#rid53">53</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Animal data</strong> – In rat models, fetal plasma levels were approximately 10 percent of maternal levels after acute exposure to delta-9-THC, the primary psychoactive cannabinoid [<a href="#rid54">54</a>]. However, repetitive exposure of THC resulted in higher fetal levels. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Human data</strong> – In comparison with animal models, studies assessing the impact of cannabis use on humans may be confounded by polysubstance use, socioeconomic factors, and the multiple chemicals present in cannabis smoke, which may be present in greater concentrations than in regular tobacco smoke [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increasing potency</strong> – In addition, contemporary cannabis products have higher quantities of THC compared with previous decades of study [<a href="#rid21">21,22,56</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A meta-analysis of 12 studies of samples from global cannabis markets reported increasing delta-9-tetrahydrocannabinol (THC) concentrations in cannabis herbal and resin products between 1970 and 2017 [<a href="#rid22">22</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An evaluation of illicit cannabis products seized in the United States reported an increase in high cannabidiol (CBD)-containing substances with an increase in overall potency from approximately 10 percent in 2009 to approximately 14 percent in 2019 [<a href="#rid21">21</a>].</p><p></p><p>Detailed discussions of pharmacology and toxicity of acute cannabis use are presented elsewhere. (See  <a class="medical medical_review" href="/d/html/97099.html" rel="external">"Cannabis (marijuana): Acute intoxication", section on 'Pharmacology and toxicity'</a>.)</p><p class="headingAnchor" id="H348917943"><span class="h2">Assessment of use</span><span class="headingEndMark"> — </span>Screening for substance use is covered in detail in related content. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4799.html" rel="external">"Substance use during pregnancy: Screening and prenatal care"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/13846.html" rel="external">"Testing for drugs of abuse (DOAs)"</a>.)</p><p></p><p>Briefly, methods to assess maternal cannabis use include patient self-report (medical history, survey) and laboratory test (urine, cord blood, meconium). Urine testing may identify both recent, infrequent use (eg, within the past two to three days) or chronic use, given cannabis's long half-life. Among chronic cannabis users, a positive urine toxicology screen may reflect either a new episode of use or continued excretion of residual drug [<a href="#rid57">57,58</a>]. Umbilical cord homogenate and meconium detect cannabis use from the second trimester onward [<a href="#rid59">59</a>]. Cord testing for the most stable metabolite, 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid, is widely used clinically. Laboratory testing typically exceeds self-report, even in states with legalized use of cannabis. For example, a cross-sectional study of 116 females giving birth in Colorado, where cannabis use is legal, reported that 22 percent had detectable 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid cord levels while far fewer self-reported use (6 percent reported use in the past month by survey and 3 percent by medical history) [<a href="#rid60">60</a>]. (See  <a class="medical medical_review" href="/d/html/7796.html" rel="external">"Cannabis use disorder: Clinical features, screening, diagnosis, and treatment", section on 'Drug testing'</a>.)</p><p class="headingAnchor" id="H2084794324"><span class="h2">Obstetric outcomes</span><span class="headingEndMark"> — </span>The impact of prenatal cannabis use on obstetric outcomes is difficult to assess because of conflicting observational data, historically small study sizes, reliance on self-reported use, wide ranges of substance exposure (eg, dose, frequency), and multiple confounding factors (eg, tobacco, alcohol, and, other substance use) [<a href="#rid61">61-63</a>]. However, the body of evidence from large population studies suggests increasing risk of spontaneous preterm birth and small for gestational age infants with prenatal cannabis exposure, although the limitations just discussed prevent definitive conclusions [<a href="#rid33">33,42,63-70</a>]. </p><p>Representative data include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Studies reporting increased risk</strong> – The studies below support increased risk of adverse obstetric outcomes but the magnitude of impact is less clear given high heterogeneity of the available data.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A 2023 meta-analysis reported prenatal cannabis use was associated with increased risks of spontaneous preterm birth (odds ratio [OR] 1.68, 95% CI 1.05-2.71, I<sup>2</sup> 99%), low birth weight (OR 2.60, 95% CI 1.71-3.94, I<sup>2</sup> 99%), and admission to a neonatal intensive care unit (OR 2.51, 95% CI 1.46-4.31, I<sup>2</sup> 100%) [<a href="#rid68">68</a>]. Limitations include low certainty evidence because of multiple differences in measuring cannabis use, imprecision as reflected in wide confidence intervals, and inherent risk of bias from observational data.  </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A 2022 meta-analysis of studies from 1983 to 2020 reported increased risk of small-for-gestational age birthweight for neonates exposed to prenatal cannabis compared with unexposed infants (&lt;fifth percentile by birth weight, risk ratio 1.61, 95% CI 1.44-1.79, six studies, n = 22,928 patients, i<sup>2 </sup>= 0 percent) [<a href="#rid64">64</a>]. While prenatal cannabis use was also significantly associated with increased risks of preterm birth (&lt;37 weeks gestation), low birth weight, lower absolute birth weight, and reduced head circumference, these results had high levels of heterogeneity and the impact of chance could not be excluded.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>No increased risk</strong> – Older studies have reported no increased risk in adverse obstetric outcomes [<a href="#rid61">61,71</a>]. In a 2016 meta-analysis of 31 studies that compared birth outcomes after cannabis use in pregnancy with no use during pregnancy, pooled adjusted analysis reported no increased risk for low birth weight (pooled relative risk 1.16, 95% CI 0.98-1.37) or preterm birth (pooled relative risk 1.08, 95% CI 0.82-1.43) [<a href="#rid61">61</a>]. Adjusted confounding factors included maternal tobacco smoking, other substance use, and selected socioeconomic and demographic factors. Limitations of this meta-analysis included relatively few individuals in the risk-adjusted group and focus on only two birth outcomes at a time when cannabis products may have been of lower potency.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Potential mechanism</strong> – A least one study comparing ultrasound findings in daily cannabis users with nonusers reported increased placental vascular resistance in daily users, which may be one mechanism of impaired growth in exposed fetuses [<a href="#rid72">72</a>].</p><p></p><p class="headingAnchor" id="H1656961671"><span class="h2">Neonatal and pediatric outcomes</span><span class="headingEndMark"> — </span>In contrast with obstetric outcomes, data suggest that cannabis use during pregnancy negatively impacts fetal/neonatal outcomes and that risk of poor outcome may be dose-dependent [<a href="#rid73">73</a>]. For the reasons detailed below, ACOG and ABM discourage cannabis use during breastfeeding [<a href="#rid18">18,19</a>]. Additional patient information can be found through ACOG's <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.acog.org%2Fwomens-health%2Ffaqs%2Fmarijuana-and-pregnancy%3Futm_source%3Dredirect%26utm_medium%3Dweb%26utm_campaign%3Dint&amp;token=fiT05NwifDBrnJK0OSzFc82SnobPuZpDrW4T7%2B%2BJdOVpK22xT5OONxOWYO7A%2FPbX5qWHnGkGrE71VEB%2BUKCaqRh5SxUPrYnzA4ZVsyJlaAMnljJG7tIosjRAu0twf3nBUi9YwlUIRQoxzTI%2BNhdecQ%3D%3D&amp;TOPIC_ID=128152" target="_blank">website</a>. (See  <a class="medical medical_review" href="/d/html/5010.html" rel="external">"Prenatal substance exposure and neonatal abstinence syndrome (NAS): Clinical features and diagnosis", section on 'Cannabis'</a> and  <a class="medical medical_review" href="/d/html/5016.html" rel="external">"Prenatal substance exposure and neonatal abstinence syndrome (NAS): Management and outcomes", section on 'Cannabis'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neonatal morbidity or death</strong> – Maternal cannabis use and cannabis use disorder (CUD) have been associated with increased risk of neonatal and infant death. In a secondary analysis of singleton, live born controls in the Stillbirth Collaborative Research Network dataset, after adjustment for tobacco, race, and other illicit drug use, cannabis use was associated with a threefold increased risk of composite neonatal morbidity or death [<a href="#rid61">61</a>]. In a California birth registry study including over 34,000 births to patients with CUD, adjusted analysis reported a 40 percent increased risk of infant death (death in first year of life) compared with patients without CUD in adjusted analysis (adjusted risk ratio 1.4, 95% CI 1.2-1.6) [<a href="#rid74">74</a>]. More research is needed to understand mechanisms by which maternal cannabis use negatively impacts offspring morbidity separate from potential confounders, such as living situation.   </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurobehavioral outcomes</strong> – Perinatal cannabis use has been associated with detrimental neurobehavioral outcomes in exposed children [<a href="#rid75">75-77</a>]. In a retrospective study of over 500,000 pregnant Canadian women who reported cannabis use, this use was associated with a 50 percent increased risk of autism spectrum disorder in offspring compared with unexposed children (adjusted hazard ratio 1.51, 95% CI 1.17-1.96) [<a href="#rid78">78</a>]. Additional studies have suggested other neurodevelopmental abnormalities [<a href="#rid79">79-81</a>]. Short- and long-term effects of maternal cannabis use on offspring are reviewed in detail separately. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/5010.html" rel="external">"Prenatal substance exposure and neonatal abstinence syndrome (NAS): Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/130622.html" rel="external">"The substance-exposed child: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Congenital anomalies </strong>– While available data do not suggest an increase in congenital anomalies among children born to people who use cannabis, the findings are mixed, limited by studies including relatively small numbers of individuals who only used cannabis, and complicated by confounders, such as lower supplemental <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> intake among people who use cannabis [<a href="#rid24">24,77,82-86</a>]. While one meta-analysis reported increased risks of Ebstein anomaly and gastroschisis for people who used cannabis compared with those who do not use cannabis, further verification is needed, as available data were limited (adjusted odds ratio [aOR] Ebstein anomaly 2.19, 95% CI 1.25-3.82, two studies and gastroschisis aOR 2.50, 95% CI 1.09-5.74, five studies) [<a href="#rid87">87</a>]. </p><p></p><p class="headingAnchor" id="H1735652429"><span class="h1">COCAINE</span></p><p class="headingAnchor" id="H3978080625"><span class="h2">Use</span><span class="headingEndMark"> — </span>Although data suggest that cocaine and other stimulant use is increasing globally [<a href="#rid88">88,89</a>], many more pregnant individuals smoke cigarettes, drink alcohol, or smoke cannabis than use cocaine [<a href="#rid90">90-95</a>]. However, data suggest that cocaine and other stimulant use is increasing globally. (See  <a class="medical medical_review" href="/d/html/7802.html" rel="external">"Cocaine use disorder: Epidemiology, clinical features, and diagnosis"</a>.)</p><p class="headingAnchor" id="H2459602503"><span class="h2">Impact on pregnancy</span><span class="headingEndMark"> — </span>Cocaine crosses the placenta and fetal blood-brain barrier; vasoconstriction is the major purported mechanism for fetal and placental damage [<a href="#rid96">96</a>]. The applicability of any of the studies on cocaine use in pregnancy is limited by methodologic shortcomings, such as failure to control for maternal age, parity, socioeconomic factors, and exposure to other drugs, alcohol, and cigarettes.</p><p>The few adequately controlled reports suggest that cocaine's effects are related to dose and stage of pregnancy. A meta-analysis including 31 studies that evaluated the relationship between maternal antenatal cocaine exposure and five adverse perinatal outcomes found cocaine use during pregnancy significantly increased the risks of [<a href="#rid97">97</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Preterm birth (odds ratio [OR] 3.38, 95% CI 2.72-4.21)</p><p class="bulletIndent1"><span class="glyph">●</span>Low birth weight (OR 3.66, 95% CI 2.90-4.63)</p><p class="bulletIndent1"><span class="glyph">●</span>Small for gestational age infant (OR 3.23, 95% CI 2.43-4.30)</p><p class="bulletIndent1"><span class="glyph">●</span>Shorter gestational age at delivery (-1.47 weeks, 95% CI -1.97 to -0.98)</p><p class="bulletIndent1"><span class="glyph">●</span>Reduced birth weight (-492 grams, 95% CI -562 to -421 grams)</p><p></p><p>Others have reported increased risks of miscarriage, abruptio placentae, and decreased length (-0.71 cm) and head circumference (-0.43 cm) at birth [<a href="#rid98">98-100</a>]. Teratogenic effects have not been definitively proven. (See  <a class="medical medical_review" href="/d/html/5010.html" rel="external">"Prenatal substance exposure and neonatal abstinence syndrome (NAS): Clinical features and diagnosis", section on 'Cocaine'</a>.)</p><p>Cardiovascular cocaine toxicity is increased in pregnant individuals [<a href="#rid96">96</a>]. Cocaine toxicity usually causes hypertension, which may mimic preeclampsia. Beta-adrenergic antagonists (ie, beta blockers) should be avoided in the treatment of cocaine-related cardiovascular complications because they create unopposed alpha-adrenergic stimulation and are associated with coronary vasoconstriction and end-organ ischemia. This contraindication includes <a class="drug drug_general" data-topicid="9540" href="/d/drug information/9540.html" rel="external">labetalol</a>, which has predominantly beta-blocking effects. <a class="drug drug_general" data-topicid="8528" href="/d/drug information/8528.html" rel="external">Hydralazine</a> is preferred for treatment of hypertension in pregnant individuals who use cocaine [<a href="#rid101">101</a>]. Decisions regarding the administration of peripartum analgesia or anesthesia need to be individualized, taking into account factors such as the combined effects of cocaine, analgesia, and anesthesia on the patient's cardiovascular and hematologic status [<a href="#rid102">102</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/303.html" rel="external">"Cocaine: Acute intoxication"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7802.html" rel="external">"Cocaine use disorder: Epidemiology, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/106878.html" rel="external">"Stimulant use disorder: Treatment overview"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4953.html" rel="external">"Clinical manifestations, diagnosis, and management of the cardiovascular complications of cocaine abuse"</a>.)</p><p></p><p class="headingAnchor" id="H4283272897"><span class="h1">AMPHETAMINES, INCLUDING METHAMPHETAMINE</span></p><p class="headingAnchor" id="H249089378"><span class="h2">Prevalence</span><span class="headingEndMark"> — </span>A diagnosis of amphetamine use disorder is becoming more common among individuals of reproductive age, including hospitalized pregnant females [<a href="#rid89">89,103-106</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>A study of 2011 to 2019 California health system data reported annual adjusted prevalence rates of methamphetamine use ranged from a high of 0.24 percent in 2014 to a low of 0.17 percent in 2019 (use defined as positive self-report or positive toxicology test) [<a href="#rid89">89</a>].  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study of US hospital discharge data, in 2014 to 2015, amphetamine use was identified in approximately 1 percent of deliveries in the rural West [<a href="#rid107">107</a>]. The study also reported amphetamine use was higher than opioid-use incidence for most areas (opioid use was higher in the Northeast). Deliveries complicated by amphetamine use had higher evidence of exposure to cannabis, cocaine, alcohol, and sedatives compared with control hospital deliveries. This study highlights the importance of screening pregnant individuals for multisubstance use.</p><p></p><p class="headingAnchor" id="H1583103209"><span class="h2">Impact</span><span class="headingEndMark"> — </span>Methamphetamine (commonly known as speed, meth, or chalk, or as ice, crystal, or glass when smoked) is a powerfully addictive stimulant. It is a known neurotoxic agent that causes release of dopamine. Amphetamines and their byproducts cross the placenta [<a href="#rid108">108</a>]. No fetal structural abnormalities have been definitively associated with perinatal amphetamine exposure [<a href="#rid109">109</a>]. However, methamphetamine exposure during pregnancy has been associated with maternal and neonatal morbidity and mortality. In studies that controlled for confounders, methamphetamine exposure was associated with a two- to fourfold increase in risk of fetal growth restriction [<a href="#rid110">110-112</a>], gestational hypertension, preeclampsia, abruption, preterm birth, intrauterine fetal demise, neonatal death, and infant death [<a href="#rid113">113</a>]. A meta-analysis of eight studies that compared pregnancy outcomes for females using methamphetamines with control individuals also reported younger gestational age at birth, lower birth weight, smaller head circumference, shorter body length, and lower Apgar scores for exposed infants [<a href="#rid114">114</a>]. The meta-analysis did not find significant differences in the rates of preeclampsia and hypertensive disorders.</p><p>Short-term neonatal effects and long-term outcomes in offspring, as well as methamphetamine use disorders and treatment of acute intoxication, are reviewed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5010.html" rel="external">"Prenatal substance exposure and neonatal abstinence syndrome (NAS): Clinical features and diagnosis", section on 'Amphetamines'</a> and  <a class="medical medical_review" href="/d/html/5016.html" rel="external">"Prenatal substance exposure and neonatal abstinence syndrome (NAS): Management and outcomes", section on 'Other substances'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/311.html" rel="external">"Methamphetamine: Acute intoxication"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14839.html" rel="external">"Methamphetamine use disorder: Epidemiology, clinical features, and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H896167090"><span class="h1">RESOURCES</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.asam.org%2F&amp;token=j%2BtF41plvYHq0KcVLVNCgoY4hnnvAP7OaxQA7ab9yeE%3D&amp;TOPIC_ID=128152" target="_blank">American Society of Addiction Medicine (ASAM)</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.samhsa.gov%2F&amp;token=vdCs7dqmABYrTYLl86e3UEFKoUxfrhkXhPK3wA2JxcE%3D&amp;TOPIC_ID=128152" target="_blank">Substance Abuse and Mental Health Services Administration (SAMHSA)</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.acog.org%2F&amp;token=IQxLzDq4doJGUgaZgeIY0zxFSMEuWanwNDC0bEdrSRs%3D&amp;TOPIC_ID=128152" target="_blank">American College of Obstetricians and Gynecologists (ACOG)</a> offers free online Frequently Asked Questions infographics addressing <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.acog.org%2Fwomens-health%2Finfographics%2Fopioid-use-disorder-and-pregnancy%3Futm_source%3Dhigher-logic%26utm_medium%3Demail%26utm_content%3Dmar-08%26utm_campaign%3Dacog2023-digest&amp;token=zNfqmduxR%2BfAkerMiR252AGB%2FofyZuHcOHEiyns6gwEiwm6OKSEXqSGcnnrpPuuylyaQxMGWFh2ocxjywOI9cFBh7B7EwqGR0CX4vugtNd4L7Sq6aoSzO5Ez%2F%2Bk3GY6cvzGmCdWFsdAejfwUyCkB0d852bPtkWRGpOCq8M2IwwTikg1r3B9r1epuaHKDmz13&amp;TOPIC_ID=128152" target="_blank">opioid</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.acog.org%2Fwomens-health%2Finfographics%2Fmarijuana-and-pregnancy%3Futm_source%3Dhigher-logic%26utm_medium%3Demail%26utm_content%3Dmar-08%26utm_campaign%3Dacog2023-digest&amp;token=OwPZhWzvbrGAVeV%2BkILoCdN7WYUuyvUpAwNWZFrH2lh2iccEe%2FVg4PJ2mQXyw5a7I%2BV9cThhRvEzSGgEv%2FBzvaQ6vyaK%2F4J5k3eJwEH4cRoAS7HBFpcoAuSnqaNMm72q5JmxUoMheuVf%2BWVplhZPus7K%2BDbmARVTxa26Cz5JvL5xooD6jWYORzGE5PEPVIHH&amp;TOPIC_ID=128152" target="_blank">cannabis</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.acog.org%2Fwomens-health%2Finfographics%2Falcohol-and-pregnancy&amp;token=kthqUQ1y8hnG9tdeSgsvsAPP2sEp2lnIQ%2BDeaC%2BA%2FHXid3G2ptRygTu9c9Mhv8LS5WtE9wEDD282h%2BQvoYtnHWK%2BcM4%2BXUVqdaLWPqjjX%2FM%3D&amp;TOPIC_ID=128152" target="_blank">alcohol</a>, and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.acog.org%2Fwomens-health%2Fsearch%23q%3Dtobacco%2520and%2520pregnancy&amp;token=5BVpFwODaaqDoux8%2Bn%2B6bP4UyszTgKJc599D5FvcxvZh0fFske%2F1J0sGA6G%2Bz%2Bb%2FPWIPUNJgQLWsniUXkYRHF2pJC8aqVge2nKrEJPJxPBg%3D&amp;TOPIC_ID=128152" target="_blank">tobacco</a> use in pregnancy. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fattcppwtools.org%2FToolkit%2FPerinatalProviderToolkit.aspx&amp;token=GFpb0%2Bx85PDQdz7g5q819aSao7HoXwbLn2LEy80WTX8c25gtVlOe12ebD30Au3imjETh4cQHZYd7XAecgo5tDw%3D%3D&amp;TOPIC_ID=128152" target="_blank">Perinatal Provider Toolkit</a> by the Mid-America Addiction Technology Transfer Center (ATTC) Network, funded by SAMHSA</p><p></p><p class="headingAnchor" id="H445127152"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/118165.html" rel="external">"Society guideline links: Substance misuse in pregnancy"</a> and  <a class="medical medical_society_guidelines" href="/d/html/113643.html" rel="external">"Society guideline links: Opioid use disorder and withdrawal"</a> and  <a class="medical medical_society_guidelines" href="/d/html/114308.html" rel="external">"Society guideline links: Cannabis use disorder and withdrawal"</a> and  <a class="medical medical_society_guidelines" href="/d/html/134144.html" rel="external">"Society guideline links: Cocaine use and cocaine use disorder"</a>.)</p><p class="headingAnchor" id="H1348441849"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/85731.html" rel="external">"Patient education: Alcohol and drug use in pregnancy (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H2998295844"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Challenges in assessing drug impact</strong> – The effect of any illicit or misused substance on pregnancy outcome is difficult to ascertain because data are scarce and confounded by the influence of other factors, including polysubstance use (particularly alcohol and tobacco products), poor nutrition, poverty, comorbid disorders, and inadequate prenatal care. In addition, reliable ascertainment of the extent of drug use during pregnancy and drug dose/purity are very difficult. (See <a class="local">'Challenges in assessing drug impact'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Opioids</strong> – Opioid use has been increasing globally. For pregnant individuals with opioid use disorder, treatment with <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> or <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> should be offered; neither drug is clearly superior, but there is more experience with methadone. Medications for opioid use disorder are associated with fewer neonatal complications and side effects than detoxification or continued use of nonprescribed opiates. Neonatal opioid withdrawal syndrome is typically less severe in neonates born to individuals treated with buprenorphine compared with individuals treated with methadone. Identification of opioid use and linkage to appropriate prenatal care are important for improved outcomes. (See <a class="local">'Opioids'</a> above.)</p><p></p><p class="bulletIndent1">Related content on opioid use disorder in pregnancy is presented separately:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/4799.html" rel="external">"Substance use during pregnancy: Screening and prenatal care"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/4790.html" rel="external">"Opioid use disorder: Overview of treatment during pregnancy"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/87238.html" rel="external">"Opioid use disorder: Pharmacotherapy with methadone and buprenorphine during pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cannabis (marijuana)</strong> – Although there is no high-quality evidence indicating an adverse effect of cannabis on obstetric outcomes, data suggest that prenatal cannabis use negatively impacts fetal/neonatal outcomes. Thus, cannabis use is discouraged during pregnancy and lactation. (See <a class="local">'Cannabis (marijuana)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cocaine</strong> – Cocaine can cause vasoconstriction of uterine vessels, which is the probable major mechanism for fetal and placental injury leading to abruptio placentae, spontaneous abortion, prematurity, and fetal death. Increased cardiovascular cocaine toxicity has also been reported for pregnant versus nonpregnant individuals. (See <a class="local">'Cocaine'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Amphetamines</strong> – Amphetamines, including methamphetamine, cross the placenta. While no fetal structural abnormalities have been definitively associated with perinatal amphetamine exposure, methamphetamine use during pregnancy has been associated with maternal and neonatal morbidity and mortality. (See <a class="local">'Amphetamines, including methamphetamine'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bruzelius E, Martins SS. US Trends in Drug Overdose Mortality Among Pregnant and Postpartum Persons, 2017-2020. JAMA 2022; 328:2159.</a></li><li><a class="nounderline abstract_t">Nguyen RHN, Knapp EA, Li X, et al. Characteristics of Individuals in the United States Who Used Opioids During Pregnancy. J Womens Health (Larchmt) 2023; 32:161.</a></li><li><a class="nounderline abstract_t">Haight SC, Ko JY, Tong VT, et al. Opioid Use Disorder Documented at Delivery Hospitalization - United States, 1999-2014. MMWR Morb Mortal Wkly Rep 2018; 67:845.</a></li><li><a class="nounderline abstract_t">Gabrielson SMB, Carwile JL, O'Connor AB, Ahrens KA. Maternal opioid use disorder at delivery hospitalization in a rural state: Maine, 2009-2018. Public Health 2020; 181:171.</a></li><li><a class="nounderline abstract_t">Desai RJ, Hernandez-Diaz S, Bateman BT, Huybrechts KF. Increase in prescription opioid use during pregnancy among Medicaid-enrolled women. Obstet Gynecol 2014; 123:997.</a></li><li><a class="nounderline abstract_t">Hirai AH, Ko JY, Owens PL, et al. Neonatal Abstinence Syndrome and Maternal Opioid-Related Diagnoses in the US, 2010-2017. JAMA 2021; 325:146.</a></li><li><a class="nounderline abstract_t">Corsi DJ, Hsu H, Fell DB, et al. Association of Maternal Opioid Use in Pregnancy With Adverse Perinatal Outcomes in Ontario, Canada, From 2012 to 2018. JAMA Netw Open 2020; 3:e208256.</a></li><li><a class="nounderline abstract_t">Venkatesh KK, Pate V, Boggess KA, et al. Trends in Opioid and Psychotropic Prescription in Pregnancy in the United States From 2001 to 2015 in a Privately Insured Population : A Cross-sectional Study. Ann Intern Med 2020; 173:S19.</a></li><li><a class="nounderline abstract_t">Bauer CR, Shankaran S, Bada HS, et al. The Maternal Lifestyle Study: drug exposure during pregnancy and short-term maternal outcomes. Am J Obstet Gynecol 2002; 186:487.</a></li><li class="breakAll">Center for Substance Abuse Treatment. Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2005. (Treatment Improvement Protocol (TIP) Series, No. 43.) Chapter 13. Medication-Assisted Treatment for Opioid Addiction During Pregnancy. www.ncbi.nlm.nih.gov/books/NBK64148/ (Accessed on June 08, 2012).</li><li><a class="nounderline abstract_t">Kaltenbach K, Berghella V, Finnegan L. Opioid dependence during pregnancy. Effects and management. Obstet Gynecol Clin North Am 1998; 25:139.</a></li><li><a class="nounderline abstract_t">Maeda A, Bateman BT, Clancy CR, et al. Opioid abuse and dependence during pregnancy: temporal trends and obstetrical outcomes. Anesthesiology 2014; 121:1158.</a></li><li><a class="nounderline abstract_t">Azuine RE, Ji Y, Chang HY, et al. Prenatal Risk Factors and Perinatal and Postnatal Outcomes Associated With Maternal Opioid Exposure in an Urban, Low-Income, Multiethnic US Population. JAMA Netw Open 2019; 2:e196405.</a></li><li><a class="nounderline abstract_t">Salihu HM, Salemi JL, Aggarwal A, et al. Opioid Drug Use and Acute Cardiac Events Among Pregnant Women in the United States. Am J Med 2018; 131:64.</a></li><li><a class="nounderline abstract_t">Carman WJ, Su S, Cook SF, et al. Coronary heart disease outcomes among chronic opioid and cyclooxygenase-2 users compared with a general population cohort. Pharmacoepidemiol Drug Saf 2011; 20:754.</a></li><li><a class="nounderline abstract_t">Committee Opinion No. 711: Opioid Use and Opioid Use Disorder in Pregnancy. Obstet Gynecol 2017; 130:e81.</a></li><li><a class="nounderline abstract_t">Suarez EA, Huybrechts KF, Straub L, et al. Buprenorphine versus Methadone for Opioid Use Disorder in Pregnancy. N Engl J Med 2022; 387:2033.</a></li><li><a class="nounderline abstract_t">Reece-Stremtan S, Marinelli KA. ABM clinical protocol #21: guidelines for breastfeeding and substance use or substance use disorder, revised 2015. Breastfeed Med 2015; 10:135.</a></li><li><a class="nounderline abstract_t">Committee Opinion No. 722: Marijuana Use During Pregnancy and Lactation. Obstet Gynecol 2017; 130:e205. Reaffirmed 2021.</a></li><li><a class="nounderline abstract_t">Ryan SA, Ammerman SD, O'Connor ME, et al. Marijuana Use During Pregnancy and Breastfeeding: Implications for Neonatal and Childhood Outcomes. Pediatrics 2018; 142.</a></li><li><a class="nounderline abstract_t">ElSohly MA, Chandra S, Radwan M, et al. A Comprehensive Review of Cannabis Potency in the United States in the Last Decade. Biol Psychiatry Cogn Neurosci Neuroimaging 2021; 6:603.</a></li><li><a class="nounderline abstract_t">Freeman TP, Craft S, Wilson J, et al. Changes in delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: systematic review and meta-analysis. Addiction 2021; 116:1000.</a></li><li><a class="nounderline abstract_t">El Marroun H, Tiemeier H, Jaddoe VW, et al. Agreement between maternal cannabis use during pregnancy according to self-report and urinalysis in a population-based cohort: the Generation R Study. Eur Addict Res 2011; 17:37.</a></li><li><a class="nounderline abstract_t">van Gelder MM, Reefhuis J, Caton AR, et al. Characteristics of pregnant illicit drug users and associations between cannabis use and perinatal outcome in a population-based study. Drug Alcohol Depend 2010; 109:243.</a></li><li><a class="nounderline abstract_t">Passey ME, Sanson-Fisher RW, D'Este CA, Stirling JM. Tobacco, alcohol and cannabis use during pregnancy: clustering of risks. Drug Alcohol Depend 2014; 134:44.</a></li><li><a class="nounderline abstract_t">Beatty JR, Svikis DS, Ondersma SJ. Prevalence and Perceived Financial Costs of Marijuana versus Tobacco use among Urban Low-Income Pregnant Women. J Addict Res Ther 2012; 3.</a></li><li><a class="nounderline abstract_t">Schempf AH, Strobino DM. Illicit drug use and adverse birth outcomes: is it drugs or context? J Urban Health 2008; 85:858.</a></li><li><a class="nounderline abstract_t">Ko JY, Farr SL, Tong VT, et al. Prevalence and patterns of marijuana use among pregnant and nonpregnant women of reproductive age. Am J Obstet Gynecol 2015; 213:201.e1.</a></li><li><a class="nounderline abstract_t">Volkow ND, Han B, Compton WM, Blanco C. Marijuana Use During Stages of Pregnancy in the United States. Ann Intern Med 2017.</a></li><li><a class="nounderline abstract_t">Volkow ND, Han B, Compton WM, McCance-Katz EF. Self-reported Medical and Nonmedical Cannabis Use Among Pregnant Women in the United States. JAMA 2019; 322:167.</a></li><li><a class="nounderline abstract_t">Young-Wolff KC, Sarovar V, Tucker LY, et al. Self-reported Daily, Weekly, and Monthly Cannabis Use Among Women Before and During Pregnancy. JAMA Netw Open 2019; 2:e196471.</a></li><li><a class="nounderline abstract_t">Ko JY, Coy KC, Haight SC, et al. Characteristics of Marijuana Use During Pregnancy - Eight States, Pregnancy Risk Assessment Monitoring System, 2017. MMWR Morb Mortal Wkly Rep 2020; 69:1058.</a></li><li><a class="nounderline abstract_t">Luke S, Hobbs AJ, Smith M, et al. Cannabis use in pregnancy and maternal and infant outcomes: A Canadian cross-jurisdictional population-based cohort study. PLoS One 2022; 17:e0276824.</a></li><li><a class="nounderline abstract_t">Kobernik EK, Ford ND, Levecke M, et al. Marijuana Use among Pregnant and Nonpregnant Women of Reproductive Age, 2013-2019. Subst Use Misuse 2023; :1.</a></li><li><a class="nounderline abstract_t">Young-Wolff KC, Sarovar V, Tucker LY, et al. Association of Depression, Anxiety, and Trauma With Cannabis Use During Pregnancy. JAMA Netw Open 2020; 3:e1921333.</a></li><li><a class="nounderline abstract_t">Goodwin RD, Zhu J, Heisler Z, et al. Cannabis use during pregnancy in the United States: The role of depression. Drug Alcohol Depend 2020; 210:107881.</a></li><li><a class="nounderline abstract_t">Meinhofer A, Hinde JM, Keyes KM, Lugo-Candelas C. Association of Comorbid Behavioral and Medical Conditions With Cannabis Use Disorder in Pregnancy. JAMA Psychiatry 2022; 79:50.</a></li><li><a class="nounderline abstract_t">Young-Wolff KC, Sarovar V, Tucker LY, et al. Association of Nausea and Vomiting in Pregnancy With Prenatal Marijuana Use. JAMA Intern Med 2018; 178:1423.</a></li><li><a class="nounderline abstract_t">Braillon A, Bewley S. Cannabinoid hyperemesis syndrome: implications for pregnancy. BMJ 2019; 366:l5587.</a></li><li><a class="nounderline abstract_t">Gnofam M, Allshouse AA, Stickrath EH, Metz TD. Impact of Marijuana Legalization on Prevalence of Maternal Marijuana Use and Perinatal Outcomes. Am J Perinatol 2020; 37:59.</a></li><li><a class="nounderline abstract_t">Agrawal A, Rogers CE, Lessov-Schlaggar CN, et al. Alcohol, Cigarette, and Cannabis Use Between 2002 and 2016 in Pregnant Women From a Nationally Representative Sample. JAMA Pediatr 2019; 173:95.</a></li><li><a class="nounderline abstract_t">Shi Y, Zhu B, Liang D. The associations between prenatal cannabis use disorder and neonatal outcomes. Addiction 2021; 116:3069.</a></li><li><a class="nounderline abstract_t">Brown QL, Sarvet AL, Shmulewitz D, et al. Trends in Marijuana Use Among Pregnant and Nonpregnant Reproductive-Aged Women, 2002-2014. JAMA 2017; 317:207.</a></li><li><a class="nounderline abstract_t">Moore DG, Turner JD, Parrott AC, et al. During pregnancy, recreational drug-using women stop taking ecstasy (3,4-methylenedioxy-N-methylamphetamine) and reduce alcohol consumption, but continue to smoke tobacco and cannabis: initial findings from the Development and Infancy Study. J Psychopharmacol 2010; 24:1403.</a></li><li><a class="nounderline abstract_t">Young-Wolff KC, Ray GT, Alexeeff SE, et al. Rates of Prenatal Cannabis Use Among Pregnant Women Before and During the COVID-19 Pandemic. JAMA 2021; 326:1745.</a></li><li><a class="nounderline abstract_t">Jarlenski M, Koma JW, Zank J, et al. Trends in perception of risk of regular marijuana use among US pregnant and nonpregnant reproductive-aged women. Am J Obstet Gynecol 2017; 217:705.</a></li><li><a class="nounderline abstract_t">Young-Wolff KC, Foti TR, Green A, et al. Perceptions About Cannabis Following Legalization Among Pregnant IndividualsWith Prenatal Cannabis Use in California. JAMA Netw Open 2022; 5.</a></li><li><a class="nounderline abstract_t">Roberts SCM, Zaugg C, Biggs MA. Association of Mandatory Warning Signs for Cannabis Use During Pregnancy With Cannabis Use Beliefs and Behaviors. JAMA Netw Open 2023; 6:e2317138.</a></li><li><a class="nounderline abstract_t">Djulus J, Moretti M, Koren G. Marijuana use and breastfeeding. Can Fam Physician 2005; 51:349.</a></li><li><a class="nounderline abstract_t">Tennes K, Avitable N, Blackard C, et al. Marijuana: prenatal and postnatal exposure in the human. NIDA Res Monogr 1985; 59:48.</a></li><li><a class="nounderline abstract_t">Perez-Reyes M, Wall ME. Presence of delta9-tetrahydrocannabinol in human milk. N Engl J Med 1982; 307:819.</a></li><li><a class="nounderline abstract_t">Wymore EM, Palmer C, Wang GS, et al. Persistence of Δ-9-Tetrahydrocannabinol in Human Breast Milk. JAMA Pediatr 2021; 175:632.</a></li><li><a class="nounderline abstract_t">Bertrand KA, Hanan NJ, Honerkamp-Smith G, et al. Marijuana Use by Breastfeeding Mothers and Cannabinoid Concentrations in Breast Milk. Pediatrics 2018; 142.</a></li><li><a class="nounderline abstract_t">Hutchings DE, Martin BR, Gamagaris Z, et al. Plasma concentrations of delta-9-tetrahydrocannabinol in dams and fetuses following acute or multiple prenatal dosing in rats. Life Sci 1989; 44:697.</a></li><li><a class="nounderline abstract_t">Moir D, Rickert WS, Levasseur G, et al. A comparison of mainstream and sidestream marijuana and tobacco cigarette smoke produced under two machine smoking conditions. Chem Res Toxicol 2008; 21:494.</a></li><li><a class="nounderline abstract_t">Metz TD, Stickrath EH. Marijuana use in pregnancy and lactation: a review of the evidence. Am J Obstet Gynecol 2015; 213:761.</a></li><li><a class="nounderline abstract_t">Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol 1992; 16:276.</a></li><li><a class="nounderline abstract_t">Musshoff F, Madea B. Review of biologic matrices (urine, blood, hair) as indicators of recent or ongoing cannabis use. Ther Drug Monit 2006; 28:155.</a></li><li><a class="nounderline abstract_t">Montgomery D, Plate C, Alder SC, et al. Testing for fetal exposure to illicit drugs using umbilical cord tissue vs meconium. J Perinatol 2006; 26:11.</a></li><li><a class="nounderline abstract_t">Metz TD, Silver RM, McMillin GA, et al. Prenatal Marijuana Use by Self-Report and Umbilical Cord Sampling in a State With Marijuana Legalization. Obstet Gynecol 2019; 133:98.</a></li><li><a class="nounderline abstract_t">Conner SN, Bedell V, Lipsey K, et al. Maternal Marijuana Use and Adverse Neonatal Outcomes: A Systematic Review and Meta-analysis. Obstet Gynecol 2016; 128:713.</a></li><li><a class="nounderline abstract_t">Metz TD, Allshouse AA, Hogue CJ, et al. Maternal marijuana use, adverse pregnancy outcomes, and neonatal morbidity. Am J Obstet Gynecol 2017; 217:478.e1.</a></li><li><a class="nounderline abstract_t">Corsi DJ, Walsh L, Weiss D, et al. Association Between Self-reported Prenatal Cannabis Use and Maternal, Perinatal, and Neonatal Outcomes. JAMA 2019; 322:145.</a></li><li><a class="nounderline abstract_t">Marchand G, Masoud AT, Govindan M, et al. Birth Outcomes of Neonates Exposed to Marijuana in Utero: A Systematic Review and Meta-analysis. JAMA Netw Open 2022; 5:e2145653.</a></li><li><a class="nounderline abstract_t">Nguyen VH, Harley KG. Prenatal Cannabis Use and Infant Birth Outcomes in the Pregnancy Risk Assessment Monitoring System. J Pediatr 2022; 240:87.</a></li><li><a class="nounderline abstract_t">Kharbanda EO, Vazquez-Benitez G, Kunin-Batson A, et al. Birth and early developmental screening outcomes associated with cannabis exposure during pregnancy. J Perinatol 2020; 40:473.</a></li><li><a class="nounderline abstract_t">Dunn ML, Bradley C, Ayonrinde OA, et al. The prevalence and significance of gestational cannabis use at an Australian tertiary hospital. Aust N Z J Obstet Gynaecol 2023; 63:6.</a></li><li><a class="nounderline abstract_t">Sorkhou M, Singla DR, Castle DJ, George TP. Birth, cognitive and behavioral effects of intrauterine cannabis exposure in infants and children: A systematic review and meta-analysis. Addiction 2023.</a></li><li><a class="nounderline abstract_t">Avalos LA, Adams SR, Alexeeff SE, et al. Neonatal outcomes associated with in utero cannabis exposure: a population-based retrospective cohort study. Am J Obstet Gynecol 2023.</a></li><li><a class="nounderline abstract_t">Metz TD, Allshouse AA, McMillin GA, et al. Cannabis Exposure and Adverse Pregnancy Outcomes Related to Placental Function. JAMA 2023; 330:2191.</a></li><li><a class="nounderline abstract_t">Warshak CR, Regan J, Moore B, et al. Association between marijuana use and adverse obstetrical and neonatal outcomes. J Perinatol 2015; 35:991.</a></li><li><a class="nounderline abstract_t">Brar BK, Patil PS, Jackson DN, et al. Effect of intrauterine marijuana exposure on fetal growth patterns and placental vascular resistance. J Matern Fetal Neonatal Med 2021; 34:3330.</a></li><li><a class="nounderline abstract_t">Haight SC, King BA, Bombard JM, et al. Frequency of cannabis use during pregnancy and adverse infant outcomes, by cigarette smoking status - 8 PRAMS states, 2017. Drug Alcohol Depend 2021; 220:108507.</a></li><li><a class="nounderline abstract_t">Bandoli G, Delker E, Schumacher BT, et al. Prenatal cannabis use disorder and infant hospitalization and death in the first year of life. Drug Alcohol Depend 2023; 242:109728.</a></li><li><a class="nounderline abstract_t">Huizink AC. Prenatal cannabis exposure and infant outcomes: overview of studies. Prog Neuropsychopharmacol Biol Psychiatry 2014; 52:45.</a></li><li><a class="nounderline abstract_t">Jansson LM, Jordan CJ, Velez ML. Perinatal Marijuana Use and the Developing Child. JAMA 2018; 320:545.</a></li><li><a class="nounderline abstract_t">Lo JO, Hedges JC, Girardi G. Impact of cannabinoids on pregnancy, reproductive health, and offspring outcomes. Am J Obstet Gynecol 2022; 227:571.</a></li><li><a class="nounderline abstract_t">Corsi DJ, Donelle J, Sucha E, et al. Maternal cannabis use in pregnancy and child neurodevelopmental outcomes. Nat Med 2020; 26:1536.</a></li><li><a class="nounderline abstract_t">Paul SE, Hatoum AS, Fine JD, et al. Associations Between Prenatal Cannabis Exposure and Childhood Outcomes: Results From the ABCD Study. JAMA Psychiatry 2021; 78:64.</a></li><li><a class="nounderline abstract_t">Grant KS, Petroff R, Isoherranen N, et al. Cannabis use during pregnancy: Pharmacokinetics and effects on child development. Pharmacol Ther 2018; 182:133.</a></li><li><a class="nounderline abstract_t">Baranger DAA, Paul SE, Colbert SMC, et al. Association of Mental Health Burden With Prenatal Cannabis Exposure From Childhood to Early Adolescence: Longitudinal Findings From the Adolescent Brain Cognitive Development (ABCD) Study. JAMA Pediatr 2022; 176:1261.</a></li><li><a class="nounderline abstract_t">Fried PA, Watkinson B, Gray R. Growth from birth to early adolescence in offspring prenatally exposed to cigarettes and marijuana. Neurotoxicol Teratol 1999; 21:513.</a></li><li><a class="nounderline abstract_t">Witter FR, Niebyl JR. Marijuana use in pregnancy and pregnancy outcome. Am J Perinatol 1990; 7:36.</a></li><li><a class="nounderline abstract_t">Fergusson DM, Horwood LJ, Northstone K, ALSPAC Study Team. Avon Longitudinal Study of Pregnancy and Childhood. Maternal use of cannabis and pregnancy outcome. BJOG 2002; 109:21.</a></li><li><a class="nounderline abstract_t">van Gelder MM, Reefhuis J, Caton AR, et al. Maternal periconceptional illicit drug use and the risk of congenital malformations. Epidemiology 2009; 20:60.</a></li><li><a class="nounderline abstract_t">Chabarria KC, Racusin DA, Antony KM, et al. Marijuana use and its effects in pregnancy. Am J Obstet Gynecol 2016; 215:506.e1.</a></li><li><a class="nounderline abstract_t">Delker E, Hayes S, Kelly AE, et al. Prenatal Exposure to Cannabis and Risk of Major Structural Birth Defects: A Systematic Review and Meta-analysis. Obstet Gynecol 2023; 142:269.</a></li><li><a class="nounderline abstract_t">Wouldes TA, Lester BM. Stimulants: How big is the problem and what are the effects of prenatal exposure? Semin Fetal Neonatal Med 2019; 24:155.</a></li><li><a class="nounderline abstract_t">Young-Wolff KC, Slama NE, Sarovar V, et al. Trends in Self-reported and Biochemically Verified Cocaine and Methamphetamine Use Among Pregnant Individuals in Northern California, 2011-2019. JAMA Netw Open 2022; 5:e2248055.</a></li><li><a class="nounderline abstract_t">Brunader RE, Brunader JA, Kugler JP. Prevalence of cocaine and marijuana use among pregnant women in a military health care setting. J Am Board Fam Pract 1991; 4:395.</a></li><li><a class="nounderline abstract_t">George SK, Price J, Hauth JC, et al. Drug abuse screening of childbearing-age women in Alabama public health clinics. Am J Obstet Gynecol 1991; 165:924.</a></li><li><a class="nounderline abstract_t">Pegues DA, Engelgau MM, Woernle CH. Prevalence of illicit drugs detected in the urine of women of childbearing age in Alabama public health clinics. Public Health Rep 1994; 109:530.</a></li><li><a class="nounderline abstract_t">Vaughn AJ, Carzoli RP, Sanchez-Ramos L, et al. Community-wide estimation of illicit drug use in delivering women: prevalence, demographics, and associated risk factors. Obstet Gynecol 1993; 82:92.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control (CDC). Statewide prevalence of illicit drug use by pregnant women--Rhode Island. MMWR Morb Mortal Wkly Rep 1990; 39:225.</a></li><li><a class="nounderline abstract_t">Buchi KF, Varner MW, Chase RA. The prevalence of substance abuse among pregnant women in Utah. Obstet Gynecol 1993; 81:239.</a></li><li><a class="nounderline abstract_t">Plessinger MA, Woods JR Jr. Maternal, placental, and fetal pathophysiology of cocaine exposure during pregnancy. Clin Obstet Gynecol 1993; 36:267.</a></li><li><a class="nounderline abstract_t">Gouin K, Murphy K, Shah PS, Knowledge Synthesis group on Determinants of Low Birth Weight and Preterm Births. Effects of cocaine use during pregnancy on low birthweight and preterm birth: systematic review and metaanalyses. Am J Obstet Gynecol 2011; 204:340.e1.</a></li><li><a class="nounderline abstract_t">Bada HS, Das A, Bauer CR, et al. Gestational cocaine exposure and intrauterine growth: maternal lifestyle study. Obstet Gynecol 2002; 100:916.</a></li><li><a class="nounderline abstract_t">Richardson GA, Hamel SC, Goldschmidt L, Day NL. Growth of infants prenatally exposed to cocaine/crack: comparison of a prenatal care and a no prenatal care sample. Pediatrics 1999; 104:e18.</a></li><li><a class="nounderline abstract_t">Bandstra ES, Morrow CE, Anthony JC, et al. Intrauterine growth of full-term infants: impact of prenatal cocaine exposure. Pediatrics 2001; 108:1309.</a></li><li><a class="nounderline abstract_t">Kuczkowski KM. The effects of drug abuse on pregnancy. Curr Opin Obstet Gynecol 2007; 19:578.</a></li><li><a class="nounderline abstract_t">Kuczkowski KM. The cocaine abusing parturient: a review of anesthetic considerations. Can J Anaesth 2004; 51:145.</a></li><li><a class="nounderline abstract_t">Cox S, Posner SF, Kourtis AP, Jamieson DJ. Hospitalizations with amphetamine abuse among pregnant women. Obstet Gynecol 2008; 111:341.</a></li><li><a class="nounderline abstract_t">Terplan M, Smith EJ, Kozloski MJ, Pollack HA. Methamphetamine use among pregnant women. Obstet Gynecol 2009; 113:1285.</a></li><li><a class="nounderline abstract_t">American College of Obstetricians and Gynecologists Committee on Health Care for Underserved Women. Committee Opinion No. 479: Methamphetamine abuse in women of reproductive age. Obstet Gynecol 2011; 117:751. Reaffirmed 2017.</a></li><li><a class="nounderline abstract_t">Oei JL, Kingsbury A, Dhawan A, et al. Amphetamines, the pregnant woman and her children: a review. J Perinatol 2012; 32:737.</a></li><li><a class="nounderline abstract_t">Admon LK, Bart G, Kozhimannil KB, et al. Amphetamine- and Opioid-Affected Births: Incidence, Outcomes, and Costs, United States, 2004-2015. Am J Public Health 2019; 109:148.</a></li><li><a class="nounderline abstract_t">Jones J, Rios R, Jones M, et al. Determination of amphetamine and methamphetamine in umbilical cord using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877:3701.</a></li><li><a class="nounderline abstract_t">Oei JL, Kingsbury A, Dhawan A, et al. Amphetamines, the pregnant woman and her children: a review. J Perinatol 2012; 32:737.</a></li><li><a class="nounderline abstract_t">Nguyen D, Smith LM, Lagasse LL, et al. Intrauterine growth of infants exposed to prenatal methamphetamine: results from the infant development, environment, and lifestyle study. J Pediatr 2010; 157:337.</a></li><li><a class="nounderline abstract_t">Arria AM, Derauf C, Lagasse LL, et al. Methamphetamine and other substance use during pregnancy: preliminary estimates from the Infant Development, Environment, and Lifestyle (IDEAL) study. Matern Child Health J 2006; 10:293.</a></li><li><a class="nounderline abstract_t">Smith LM, LaGasse LL, Derauf C, et al. The infant development, environment, and lifestyle study: effects of prenatal methamphetamine exposure, polydrug exposure, and poverty on intrauterine growth. Pediatrics 2006; 118:1149.</a></li><li><a class="nounderline abstract_t">Gorman MC, Orme KS, Nguyen NT, et al. Outcomes in pregnancies complicated by methamphetamine use. Am J Obstet Gynecol 2014; 211:429.e1.</a></li><li><a class="nounderline abstract_t">Kalaitzopoulos DR, Chatzistergiou K, Amylidi AL, et al. Effect of Methamphetamine Hydrochloride on Pregnancy Outcome: A Systematic Review and Meta-analysis. J Addict Med 2018; 12:220.</a></li></ol></div><div id="topicVersionRevision">Topic 128152 Version 32.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36472602" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : US Trends in Drug Overdose Mortality Among Pregnant and Postpartum Persons, 2017-2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36350685" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Characteristics of Individuals in the United States Who Used Opioids During Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30091969" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Opioid Use Disorder Documented at Delivery Hospitalization - United States, 1999-2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32065884" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Maternal opioid use disorder at delivery hospitalization in a rural state: Maine, 2009-2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24785852" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Increase in prescription opioid use during pregnancy among Medicaid-enrolled women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33433576" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Neonatal Abstinence Syndrome and Maternal Opioid-Related Diagnoses in the US, 2010-2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32725246" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Association of Maternal Opioid Use in Pregnancy With Adverse Perinatal Outcomes in Ontario, Canada, From 2012 to 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33253018" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Trends in Opioid and Psychotropic Prescription in Pregnancy in the United States From 2001 to 2015 in a Privately Insured Population : A Cross-sectional Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11904612" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The Maternal Lifestyle Study: drug exposure during pregnancy and short-term maternal outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11904612" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The Maternal Lifestyle Study: drug exposure during pregnancy and short-term maternal outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9547764" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Opioid dependence during pregnancy. Effects and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25405293" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Opioid abuse and dependence during pregnancy: temporal trends and obstetrical outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31251378" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Prenatal Risk Factors and Perinatal and Postnatal Outcomes Associated With Maternal Opioid Exposure in an Urban, Low-Income, Multiethnic US Population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28807713" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Opioid Drug Use and Acute Cardiac Events Among Pregnant Women in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21567652" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Coronary heart disease outcomes among chronic opioid and cyclooxygenase-2 users compared with a general population cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28742676" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Committee Opinion No. 711: Opioid Use and Opioid Use Disorder in Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36449419" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Buprenorphine versus Methadone for Opioid Use Disorder in Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25836677" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : ABM clinical protocol #21: guidelines for breastfeeding and substance use or substance use disorder, revised 2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28937574" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Committee Opinion No. 722: Marijuana Use During Pregnancy and Lactation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30150209" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Marijuana Use During Pregnancy and Breastfeeding: Implications for Neonatal and Childhood Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33508497" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A Comprehensive Review of Cannabis Potency in the United States in the Last Decade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33160291" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Changes in delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20975275" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Agreement between maternal cannabis use during pregnancy according to self-report and urinalysis in a population-based cohort: the Generation R Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20171023" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Characteristics of pregnant illicit drug users and associations between cannabis use and perinatal outcome in a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24095245" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Tobacco, alcohol and cannabis use during pregnancy: clustering of risks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23858392" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Prevalence and Perceived Financial Costs of Marijuana versus Tobacco use among Urban Low-Income Pregnant Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18791865" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Illicit drug use and adverse birth outcomes: is it drugs or context?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25772211" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Prevalence and patterns of marijuana use among pregnant and nonpregnant women of reproductive age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28418460" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Marijuana Use During Stages of Pregnancy in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31211824" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Self-reported Medical and Nonmedical Cannabis Use Among Pregnant Women in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31322686" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Self-reported Daily, Weekly, and Monthly Cannabis Use Among Women Before and During Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32790656" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Characteristics of Marijuana Use During Pregnancy - Eight States, Pregnancy Risk Assessment Monitoring System, 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36417349" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Cannabis use in pregnancy and maternal and infant outcomes: A Canadian cross-jurisdictional population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38132561" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Marijuana Use among Pregnant and Nonpregnant Women of Reproductive Age, 2013-2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32074285" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Association of Depression, Anxiety, and Trauma With Cannabis Use During Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32143978" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Cannabis use during pregnancy in the United States: The role of depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34730782" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Association of Comorbid Behavioral and Medical Conditions With Cannabis Use Disorder in Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30128499" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Association of Nausea and Vomiting in Pregnancy With Prenatal Marijuana Use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31548251" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Cannabinoid hyperemesis syndrome: implications for pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31491805" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Impact of Marijuana Legalization on Prevalence of Maternal Marijuana Use and Perinatal Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30398527" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Alcohol, Cigarette, and Cannabis Use Between 2002 and 2016 in Pregnant Women From a Nationally Representative Sample.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33887075" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The associations between prenatal cannabis use disorder and neonatal outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27992619" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Trends in Marijuana Use Among Pregnant and Nonpregnant Reproductive-Aged Women, 2002-2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19939863" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : During pregnancy, recreational drug-using women stop taking ecstasy (3,4-methylenedioxy-N-methylamphetamine) and reduce alcohol consumption, but continue to smoke tobacco and cannabis: initial findings from the Development and Infancy Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34570168" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Rates of Prenatal Cannabis Use Among Pregnant Women Before and During the COVID-19 Pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28843740" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Trends in perception of risk of regular marijuana use among US pregnant and nonpregnant reproductive-aged women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Perceptions About Cannabis Following Legalization Among Pregnant IndividualsWith Prenatal Cannabis Use in California</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37314807" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Association of Mandatory Warning Signs for Cannabis Use During Pregnancy With Cannabis Use Beliefs and Behaviors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15794018" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Marijuana use and breastfeeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3929132" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Marijuana: prenatal and postnatal exposure in the human.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6287261" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Presence of delta9-tetrahydrocannabinol in human milk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33683306" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Persistence ofΔ-9-Tetrahydrocannabinol in Human Breast Milk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30150212" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Marijuana Use by Breastfeeding Mothers and Cannabinoid Concentrations in Breast Milk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2538691" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Plasma concentrations of delta-9-tetrahydrocannabinol in dams and fetuses following acute or multiple prenatal dosing in rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18062674" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : A comparison of mainstream and sidestream marijuana and tobacco cigarette smoke produced under two machine smoking conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25986032" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Marijuana use in pregnancy and lactation: a review of the evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1338215" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16628124" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Review of biologic matrices (urine, blood, hair) as indicators of recent or ongoing cannabis use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16281047" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Testing for fetal exposure to illicit drugs using umbilical cord tissue vs meconium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30531577" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Prenatal Marijuana Use by Self-Report and Umbilical Cord Sampling in a State With Marijuana Legalization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27607879" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Maternal Marijuana Use and Adverse Neonatal Outcomes: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28578174" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Maternal marijuana use, adverse pregnancy outcomes, and neonatal morbidity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31211826" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Association Between Self-reported Prenatal Cannabis Use and Maternal, Perinatal, and Neonatal Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35084479" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Birth Outcomes of Neonates Exposed to Marijuana in Utero: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34508747" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Prenatal Cannabis Use and Infant Birth Outcomes in the Pregnancy Risk Assessment Monitoring System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31911642" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Birth and early developmental screening outcomes associated with cannabis exposure during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35851950" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The prevalence and significance of gestational cannabis use at an Australian tertiary hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37968824" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Birth, cognitive and behavioral effects of intrauterine cannabis exposure in infants and children: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38029850" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Neonatal outcomes associated with in utero cannabis exposure: a population-based retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38085313" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Cannabis Exposure and Adverse Pregnancy Outcomes Related to Placental Function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26401751" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Association between marijuana use and adverse obstetrical and neonatal outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31711334" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Effect of intrauterine marijuana exposure on fetal growth patterns and placental vascular resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33476951" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Frequency of cannabis use during pregnancy and adverse infant outcomes, by cigarette smoking status - 8 PRAMS states, 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36516553" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Prenatal cannabis use disorder and infant hospitalization and death in the first year of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24075896" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Prenatal cannabis exposure and infant outcomes: overview of studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30014136" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Perinatal Marijuana Use and the Developing Child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35662548" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Impact of cannabinoids on pregnancy, reproductive health, and offspring outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32778828" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Maternal cannabis use in pregnancy and child neurodevelopmental outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32965490" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Associations Between Prenatal Cannabis Exposure and Childhood Outcomes: Results From the ABCD Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28847562" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Cannabis use during pregnancy: Pharmacokinetics and effects on child development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36094599" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Association of Mental Health Burden With Prenatal Cannabis Exposure From Childhood to Early Adolescence: Longitudinal Findings From the Adolescent Brain Cognitive Development (ABCD) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10492386" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Growth from birth to early adolescence in offspring prenatally exposed to cigarettes and marijuana.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2294909" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Marijuana use in pregnancy and pregnancy outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11843371" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Maternal use of cannabis and pregnancy outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19057385" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Maternal periconceptional illicit drug use and the risk of congenital malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27263998" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Marijuana use and its effects in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37473409" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Prenatal Exposure to Cannabis and Risk of Major Structural Birth Defects: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30803902" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Stimulants: How big is the problem and what are the effects of prenatal exposure?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36542384" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Trends in Self-reported and Biochemically Verified Cocaine and Methamphetamine Use Among Pregnant Individuals in Northern California, 2011-2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1767690" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Prevalence of cocaine and marijuana use among pregnant women in a military health care setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1951555" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Drug abuse screening of childbearing-age women in Alabama public health clinics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8041853" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Prevalence of illicit drugs detected in the urine of women of childbearing age in Alabama public health clinics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8515933" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Community-wide estimation of illicit drug use in delivering women: prevalence, demographics, and associated risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2319999" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Statewide prevalence of illicit drug use by pregnant women--Rhode Island.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8423958" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : The prevalence of substance abuse among pregnant women in Utah.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8513624" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Maternal, placental, and fetal pathophysiology of cocaine exposure during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21257143" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Effects of cocaine use during pregnancy on low birthweight and preterm birth: systematic review and metaanalyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12423853" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Gestational cocaine exposure and intrauterine growth: maternal lifestyle study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10429136" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Growth of infants prenatally exposed to cocaine/crack: comparison of a prenatal care and a no prenatal care sample.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11731653" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Intrauterine growth of full-term infants: impact of prenatal cocaine exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18007137" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : The effects of drug abuse on pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14766691" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : The cocaine abusing parturient: a review of anesthetic considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18238971" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Hospitalizations with amphetamine abuse among pregnant women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19461424" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Methamphetamine use among pregnant women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21343793" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Committee Opinion No. 479: Methamphetamine abuse in women of reproductive age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22652562" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Amphetamines, the pregnant woman and her children: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30496001" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Amphetamine- and Opioid-Affected Births: Incidence, Outcomes, and Costs, United States, 2004-2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19783234" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Determination of amphetamine and methamphetamine in umbilical cord using liquid chromatography-tandem mass spectrometry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22652562" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Amphetamines, the pregnant woman and her children: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20570284" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Intrauterine growth of infants exposed to prenatal methamphetamine: results from the infant development, environment, and lifestyle study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16395620" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Methamphetamine and other substance use during pregnancy: preliminary estimates from the Infant Development, Environment, and Lifestyle (IDEAL) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16951010" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : The infant development, environment, and lifestyle study: effects of prenatal methamphetamine exposure, polydrug exposure, and poverty on intrauterine growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24905417" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Outcomes in pregnancies complicated by methamphetamine use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29509557" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Effect of Methamphetamine Hydrochloride on Pregnancy Outcome: A Systematic Review and Meta-analysis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
